The Association of Serum Leptin with Mortality in Older Adults

Suruchi Mishra\(^1\)\(^*,\) Tamara B. Harris\(^2\)\(*\), Wen-Chi Hsueh\(^3\)\(*\), Trisha Hue\(^4\)\(*\), Tennille S. Leak\(^5\)\(*\), Rongling Li\(^6\)\(*\), Mira Mehta\(^1\)\(*\), Christian Vaisse\(^7\)\(*\), Nadine R. Sahyoun\(^1\)\(*\)

1 Department of Nutrition and Food Science, University of Maryland, College Park, Maryland, United States of America, 2 National Institute on Aging, National Institute of Health, Bethesda, Maryland, United States of America, 3 Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Phoenix, Arizona, United States of America, 4 University of California San Francisco, San Francisco, California, United States of America, 5 Michigan Public Health Institute, Okemos, Michigan, United States of America, 6 National Human Genome Research Institute, National Institute of Health, Rockville, Maryland, United States of America, 7 Diabetes Center and Department of Medicine, University of California San Francisco, San Francisco, California, United States of America

\(^*\) These authors contributed equally to this work.
\(^\dagger\) These authors also contributed equally to this work.

Abstract

Objective

Elevated levels of serum leptin are associated with increased adiposity and production of pro-inflammatory cytokines. Both cytokines and body adiposity have been shown to predict cardiovascular events and mortality. The primary objective of the present study is to explore the associations between serum leptin and all-cause mortality and mortality from cardiovascular disease (CVD) over a span of 10 years, controlling for body adiposity and pro-inflammatory cytokines.

Methods

The Health, Aging and Body Composition (Health ABC) study is a prospective cohort of 3,075 older adults aged 70 to 79 years. This analysis includes 2,919 men and women with complete serum leptin and vital status data. Data on all-cause mortality and incident cardiovascular events (including Coronary Heart Disease and Congestive Heart Failure) were collected over 10 years of follow-up (mean 8.4 years).

Results

Women with leptin in quartile 2 and 3 were at lower risk of all-cause mortality, and those with leptin in quartile 2 were at lower risk of mortality from CVD as compared to women with lowest leptin values when adjusted for age, race, site, years of education, alcohol use, smoking, and physical activity. When these associations were additionally adjusted for body fat, C-reactive protein and pro-inflammatory cytokines, women with leptin values in quartile 3 were at lower risk of all-cause mortality and women with leptin in quartile 2 and 3...
were at lower risk of mortality from CVD than women with lowest leptin values. These associations were not significant among men after adjusting for body fat and cytokines.

Conclusions
The present study suggests that moderately elevated concentrations of serum leptin are independently associated with lower risk of all-cause mortality and CVD-related mortality among older women. Among men, serum leptin is not associated with reduced risk of all-cause and CVD mortality after controlling for body fat and cytokines.

Introduction
Leptin plays a critical role in energy intake [1, 2], inflammatory response [3], and is strongly correlated with body fat [3, 4, 5, 6], which is linked to mortality [7, 8, 9]. Serum leptin and proinflammatory cytokines have been associated in the development of several age-associated conditions such as metabolic syndrome and atherosclerosis [7, 10, 11, 12, 13, 14, 15]. With aging, there is a concomitant increase in the levels of serum leptin, proinflammatory cytokines [3, 7, 16, 17, 18] that are linked to obesity [1, 19], and the prevalence of metabolic diseases [1, 14, 20, 21, 22, 23, 24]. Leptin and its receptor have structural and functional similarities with the interleukin-6 (IL-6) family of cytokines [13] and high levels of IL-6 were associated with cardiovascular and other causes of mortality among healthy older adults [7]. Increases in tumor necrosis factor-α (TNF-α) and serum leptin levels with aging have been associated with obesity and atherosclerosis [25, 26, 27, 28]. Previous studies on the role of leptin on cardiovascular function have shown conflicting results. Leptin exerts protective effect on cardiovascular function by modulating nitric oxide synthesis in human endothelial cell culture study [29]. However, hyperleptinemia induces chronic oxidative stress in endothelial cells and activates atherogenic process in vitro models [17]. In some population based studies, elevated levels of leptin have been shown to be associated with increased risk of metabolic syndrome [24, 15] and incident coronary artery disease [23], while others found no association [30, 31].

Although serum levels of leptin have been consistently shown to be associated with increased inflammation and morbidity, the association of leptin with survival has not been well-studied independently of inflammatory factors and body adiposity among functionally well older adults.

The primary objective of this analysis was to examine the association between serum leptin and the risk of all-cause mortality and CVD-related mortality over a 10-year follow-up and to investigate whether these associations are independent of markers of inflammation and body fat.

Methods
The study is secondary data analysis and was approved by IRB Office, University of Maryland, College Park, Lee Building, Room 2100, Zip 5125, College Park, Maryland 20742. IRB APPLICATION # 09–0527. Written informed consent was given by participants in the Health ABC study for their clinical records to be used.

Study Design
The Health ABC study is a longitudinal cohort study of 3,075 community-dwelling, well-functioning white and black men and women aged 70 to 79 years at the commencement of the
study. This study was described in details elsewhere [32]. Briefly, participants were recruited for the study from a random sample of white residents receiving Medicare benefits and all age-eligible black residents of Pittsburgh, Pennsylvania, and Memphis, Tennessee. The subjects were considered eligible to participate in the study if they reported no difficulty walking a quarter of a mile, climbing 10 steps without resting, or performing basic activities of daily living, were free of life-threatening illness, and planned to remain in the geographic area for at least 3 years. Those who reported active treatment for cancer or participation in diet or exercise intervention were excluded from the study. Participants gave written informed consent, and protocols were approved by the Institutional Review Boards at the two study sites. The participants’ information was anonymized and de-identified prior to analysis. Enrollment in the cohort and baseline clinic visits, which included collection of serum and measures of body composition, weight-related health conditions, and physical function, were conducted between April 1997 and June 1998. Thereafter, clinical examinations to obtain follow-up body composition measures and clinical outcome data were conducted annually for six years, and then every other year through year 10. Semi-annual phone interviews were also conducted between clinic visits to ascertain outcome data.

**Subjects**

In the present analysis, data from baseline through year 10 of the Health ABC study were used. The sample size for this analysis was 2,919 (men = 1,419; women = 1,500) after excluding those with incomplete information for vital status (n = 101) and missing serum leptin (n = 55). One hundred thirteen (n = 113) participants were missing data for total percent body fat, 119 for abdominal visceral fat, 209 for abdominal subcutaneous fat, 203 for TNF-α, 38 for C-reactive protein (CRP), 65 for plasminogen activator inhibitor-1 (PAI-1) and 162 for IL-6. The number of participants missing information for these variables did not differ by the outcome variable.

**Baseline Biochemical Markers**

Blood samples were collected in the morning when participants underwent venipuncture at the baseline visit after an overnight fast, and serum samples were frozen at -70°C. Both IL-6 and TNF-α were measured in duplicate using an ultrasensitive enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). The limit of detection was 0.10 pg/ml for IL-6 and 0.18 pg/ml for TNF-α. The level of PAI-1 was measured in citrated plasma samples using a 2-site enzyme-linked immunosorbent assay. Serum levels of CRP were also measured in duplicate by enzyme-linked immunosorbent assay based on purified protein and polyclonal anti-CRP antibodies (Calbiochem, San Diego, CA, USA) with a coefficient of variation of 8.0%. Serum concentrations of leptin were measured in duplicate by means of radioimmunoassay (Linco Research Inc, St Charles, MO, USA). The assay range is 0.05 to 100 ng/ml leptin in serum. Intra-assay CVs ranged from 3.7% to 7.5%, and inter-assay CVs ranged from 3.2% to 8.9%.

**Baseline Anthropometric Variables**

Weight was measured in kilograms using a standard balance beam scale. Height was measured twice in centimeters using a Harpenden stadiometer (Holtain Ltd., Crosswell, U.K.) and the average of the two measurements was used. BMI [weight (kg)/height (m²)] was calculated. Dual energy x-ray absorptiometry (DXA) (Hologic QDR 4500A, software version 8.21, Hologic, Waltham, MA, USA) was used to assess total fat mass and total percentage of body fat was calculated.
Demographic and Lifestyle Variables

A standardized questionnaire was administered at baseline to collect information on sociodemographic variables including age, gender, self-identified race, years of education, and lifestyle variables including smoking status and average alcohol consumption during the past year. Information on use of estrogen or female hormone pills (Hormonal Replacement Therapy, HRT) since menopause was also collected from women. Cigarette packs smoked per day were multiplied by the number of years of smoking to calculate the pack-years over a lifetime of cigarette smoking. Level of physical activity was ascertained by a standardized questionnaire specifically designed for the Health ABC study [33]. The frequency, duration, and intensity level of activities such as self-report of walking and exercise were recorded, and approximate values of metabolic equivalent unit (MET) were assigned to each activity category to estimate weekly energy expenditure in kcal/kg/week. Dietary calorie intake was measured during Year 2 of the Health ABC Study, at the first annual follow-up visit using a 108-item food frequency questionnaire (FFQ) that was designed to assess intake in the year prior. Nutrient and food group intakes were determined by Block Dietary Data Systems [34].

Outcome Variables

All deaths were adjudicated by a central committee. The outcomes included in this analysis were all-cause mortality, and CVD-related mortality events occurring between baseline through November 26, 2007. Every 6 months, participants either received an in-person examination or were contacted by telephone. Deaths were also ascertained through review of death certificates, hospital records, proxy interviews, and Social Security Death Index data. All deaths in Health ABC were adjudicated by a central committee. CVD-related death was defined as any death where the underlying cause was confirmed as atherosclerotic cardiovascular disease (definite fatal myocardial infarction, or definite or possible fatal coronary artery disease), cerebrovascular disease, atherosclerotic disease other than cardiovascular, and other cardiovascular disease.

Statistical Analysis

Serum leptin values and body fat vary by gender; therefore, the analysis was performed separately by gender [15, 35]. Baseline characteristics of men and women were examined by quartiles of serum leptin. For continuous variables, least square means were computed with Dunnett’s test option, and for categorical variables, the chi-square test was used to compare the means of quartile 2 through 4 to those of quartile 1. The inflammatory markers and leptin was log transformed because they were not normally distributed. The correlations between explanatory variables (age, smoking status, exercise, total percent fat, leptin, CRP, IL-6, TNF-α, and PAI-1) were examined and multicollinearity was assessed by using variance inflation factors (VIF). The VIF remained below the suggested cut off value of four for all explanatory variables. Interactions between serum leptin with race, inflammatory markers (CRP, IL-6, TNF-α, and PAI-1), adiposity measures (total percent fat) and CVD diagnosis were tested; none were statistically significant based on alpha level of 0.05.

Survival time was defined as the time from the date of the baseline visit until the date of death and/or date of last contact. Cox proportional hazard regression analysis was used to assess the risk of all-cause mortality and mortality from CVD for persons in quartiles 2 through 4 of serum leptin with those in quartile 1. The regression models were sequentially adjusted for potential confounders (age, gender, race, study site, education, smoking status, alcohol use, physical activity, HRT use, and number of hours fasted), total percent fat and markers of systemic inflammation (CRP, TNF-α, IL-6 and PAI-1). Final model included the main predictor
variable (leptin) and covariates that were significantly associated with the outcome. Log transformed leptin was used in linear regression model for trend analysis. All the covariates met the assumptions for proportional hazard regression.

Statistical significance was set at \(p \leq 0.05\), and analysis was performed using SAS software program (version 9.1; SAS Institute Inc., Cary, NC).

**Results**

There was a significant difference (\(p<0.0001\)) between the mean serum leptin concentrations of men 7.9 (±6.9) ng/ml and women 21.3 (±14.6) ng/ml. Baseline characteristics indicate that a lower percentage of men and women in quartile 4 of serum leptin consumed alcohol than those in quartile 1. Men in quartile 3 were more likely to be white and have completed high school, as compared to those in quartile 1. Women in quartile 2, 3, and 4 were less likely to be white and those in quartile 3 and 4 were less likely to complete high school as compared to those in quartile 1. As expected, men and women with leptin in quartile 1 had significantly lower BMI and total percent body fat as compared to those with higher serum leptin, Tables 1 and 2.

Women in quartile 1 had significantly lower CRP and IL-6 levels than those in quartile 3 and 4. Individuals (men and women) with leptin in quartile 1 had significantly lower TNF-\(\alpha\) than those in quartile 4 and significantly lower PAI-1 than those in quartiles 2, 3, and 4.

Serum leptin was significantly correlated with age, race, site, smoking, alcohol use (\(p<0.001\), \(r\) ranged from -0.14 to 0.12), total percent body fat (\(p<0.0001\), \(r = 0.79\)), cytokines (TNF-\(\alpha\), IL-6, and PAI-1) (\(p<0.001\), \(r\) ranged from 0.04 to 0.27) and CRP (\(p<0.0001\), \(r = 0.24\)). These variables were included in the multivariable models.

The average follow-up time from baseline was 8.4 years, with a range of 1.1 to 10.4 years. During the follow-up time, 556 (39.2%) men and 401 (26.7%) women were deceased. Among men, there was no significant association between serum leptin and all-cause mortality. Among women, those with serum leptin values in quartile 2 (\(HR = 0.71; 95\% CI = 0.53, 0.95\)) and 3 (\(HR = 0.73; 95\% CI = 0.55, 0.98\)) had significantly lower risk of mortality as compared to those in quartile 1 after adjusting for age, race, site, years of education, alcohol use, smoking, and physical activity in model 1. With further adjustment for total percent fat and proinflammatory cytokines, the association between quartile 3 of serum leptin and all-cause mortality remained marginally significant (\(HR = 0.68; 95\% CI = 0.47, 0.99\)). As indicated by the trend analysis, the association between leptin and mortality was not linear. No associations were found among men, Table 3.

During follow-up, 197 (13.9%) men and 154 (10.3%) women died due to mortality from CVD. There were no significant associations between risk for CVD-related mortality and serum leptin levels among men. Women with leptin levels in quartile 2 (\(HR = 0.60; 95\% CI = 0.37, 0.97\)) were at lower risk for CVD-related mortality, as compared to women with leptin levels in quartile 1 after adjustment for potential confounders. When percent body fat and inflammatory markers were added to the model, women with leptin values in quartile 2 and 3 were at lower risk for mortality from CVD (\(HR = 0.52; 95\% CI = 0.28, 0.97\) and \(HR = 0.44; 95\% CI = 0.22, 0.89\), respectively) as compared to those with leptin values in lowest quartile. No linear associations were found between leptin and the risk of mortality from CVD among men and women, Table 3.

**Discussion**

In the present study intermediate levels of serum leptin were associated with lower risk of all-cause mortality and CVD-related mortality. These associations remained significant after controlling for measures of body adiposity and the pro-inflammatory cytokines.
Results of this study are supported by previous studies that have shown an association between serum leptin and all-cause and CVD mortality [8, 17, 36]. Lieb et al., in Framingham Heart Study found a U-shaped association between serum leptin and all-cause mortality with elevated risk of death at both low and high levels of leptin among older men and women [36]. Furthermore, they showed that the U-shape association was mainly contributed by increased risk of death due to non-cardiovascular diseases [36]. Hypoleptinemia has been shown to elevate the risk of cancer mortality [37], while hyperleptinemia increased the risk of mortality from type 2 diabetes [38]. In a longitudinal study of impaired glucose-tolerant and diabetic women aged 49 to 73 years, CVD mortality significantly decreased in intermediate and higher tertiles as compared to lowest tertile of serum leptin concentrations [27]. In the Heart and Soul Study, low leptin was associated with 37% increased risk of cardiovascular events in patients with mean age of 67 years and stable coronary artery disease after adjusting for obesity and traditional cardiovascular risk factors [8]. In our study, we investigated gender specific associations of leptin with risk of all-cause and CVD-related mortality among functionally well older adults. Our results of an inverse association between leptin levels and all-cause and CVD mortality at moderately elevated, but not at high, levels of leptin among older women are consistent with previous reports.

Additionally, we showed that this association remained significant after controlling for body fat and cytokines among older women but not among older men. Studies have consistently shown that women have higher serum leptin concentrations independent of total body fat mass or percent fat [39, 40]. Compared to older men, higher serum leptin concentrations in

Table 1. Baseline characteristics of men by serum leptin quartilea.

| Serum Leptin Quartile | 1     | 2     | 3     | 4     |
|-----------------------|-------|-------|-------|-------|
| Men (n)               | 354   | 355   | 355   | 355   |
| Mean Serum Leptin (ng/ml)c | 2.11±0.93 | 4.77±0.76 | 7.92±1.13 | 16.97±8.13 |
| **Demographic and behavioral variables** |       |       |       |       |
| Age (years)c          | 75.4±2.9 | 75.1±2.5 | 75.4±3.0 | 75.2±2.8 |
| Race (% white)c       | 62     | 67     | 69b    | 56     |
| Alcohol use (% any consumption)c | 64     | 60     | 55     | 53b    |
| Education (% completed high school)c | 69     | 73     | 76b    | 74     |
| Smoking (lifetime pack-years)c | 25.2±29.6 | 25.2±29.5 | 25.4±31.9 | 27.1±31.1 |
| Physical activity (kcal/kg/week)c | 9.35±20.6 | 8.8±20.9 | 7.7±17.1 | 7.4±15.5 |
| **Dietary and anthropometric variables** |       |       |       |       |
| Total calorie intake (kcal)d | 2128±867 | 2084±849 | 1991±798 | 1875±775 |
| BMI (kg/m²)c          | 23.75±2.7 | 26.1±2.8b | 28.1±2.9b | 30.2±3.9b |
| Total body fat (%)c   | 24.1±3.8 | 28.2±3.0b | 31.2±3.4b | 33.3±4.2b |
| **Biochemical markers** |       |       |       |       |
| C-reactive protein (µg/ml)c | 2.44±4.3 | 2.7±5.0 | 2.7±5.4 | 2.8±3.1 |
| IL-6 (pg/ml)c         | 2.46±2.1 | 2.27±1.62 | 2.55±2.1 | 2.6±1.8 |
| TNF-alpha (pg/ml)c    | 3.5±1.8 | 3.5±2.1 | 3.6±1.5 | 3.9±1.9b |
| PAI-I c               | 22.6±1.0 | 28.1±1.1b | 28.1±1.1b | 27.5±1.3b |

a Means (±SEM), unless otherwise specified.
b Significantly different from leptin quartile 1, P<0.05 (Dunnett’s test for continuous variables and chi-square test for categorical variables).
c Values from baseline of the Health ABC study.
d Values from year 2 of the Health ABC study.

doi:10.1371/journal.pone.0140763.t001
older women were not fully explained by visceral and subcutaneous adipose tissues [41, 42]. The protective effect of moderately elevated serum leptin levels on all-cause mortality and CVD-related mortality among older women also suggests that differences in effects of hormones on physiology may be one of the several explanations for gender disparity in mortality rates.

Some studies found positive associations between elevated serum leptin and the risk factors for cardiovascular disease among healthy and diabetic individuals [9, 10, 13, 21, 23, 43]. However, others have shown that elevated leptin reduces cardiomyocyte lipotoxicity by promoting fatty acid oxidation [44, 45] and provides a compensatory role for the reduced cardiac output and improves survival [45]. Leptin has receptors on cardiac myocytes, which exerts direct anti-hypertrophic effects in heart by stimulating nitric oxide signaling [46]. Levels of serum leptin may have protective effect on cardiac function. Impaired leptin signaling, as in state of hyperleptinemia [47, 48], leads to development of left ventricular hypertrophy [46], and induces chronic oxidative stress in endothelial cells and activates atherogenic process in vitro models [17]. Obesity has been consistently linked with the risk of developing cardiovascular disease and heart failure [8, 10], however several previous studies indicated association between overweight and obesity and increased survival in patients with heart failure, which is known as ‘obesity paradox’ [8]. Leptin is secreted by adipose tissue [41] and has been shown to be positively associated with BMI [25] and percent body fat [3, 41]. The protective role of obesity in survival

| Table 2. Baseline characteristics of women by serum leptin quartilea. |
|---------------------------------------------------------------|
| **Serum Leptin Quartile** | 1 | 2 | 3 | 4 |
| **Women (n)** | 375 | 375 | 375 | 375 |
| **Mean Serum Leptin (ng/ml)** | 6.4 (±2.6) | 14.0 (±2.2) | 22.7 (±2.9) | 42.1 (±11.1) |
| **Demographic and behavioral variables** | | | | |
| Age (years) | 75.3 (±2.9) | 75.3 (±2.9) | 75.0 (±2.8) | 75.0 (±2.8) |
| Race (% white) | 71 | 59b | 51b | 61b |
| Alcohol use (% any consumption) | 45 | 47 | 44 | 35b |
| Education (% completed high school) | 84 | 78 | 77b | 70b |
| Smoking (lifetime pack-years) | 14.2 (±25.2) | 10.6 (±18.7) | 13.4 (±25.6) | 11.2 (±21.8) |
| Physical activity (kcal/kg/week) | 5.1 (±11.8) | 4.6 (±10.3) | 2.9 (±7.5)b | 3.9 (±15.6) |
| HRT use (% yes) | 41 | 44 | 42 | 38 |
| **Dietary and anthropometric variables** | | | | |
| Total calorie intake (kcal) | 1731 (±627) | 1717 (±684) | 1701 (±657) | 1677 (±629) |
| BMI (kg/m2) | 23.1 (±3.7) | 26.4 (±3.9)b | 29.0 (±4.3)b | 32.3 (±4.9)b |
| Total body fat (%) | 35.0 (±5.4) | 39.5 (±3.9)b | 42.2 (±3.7)b | 45.0 (±4.1)b |
| **Biochemical markers** | | | | |
| C-reactive protein (μg/ml) | 2.6 (±5.6) | 2.6 (±2.4) | 3.7 (±4.6)b | 4.3 (±5.2)b |
| IL-6 (pg/ml) | 2.0 (±1.8) | 1.9 (±1.5) | 2.5 (±2.1)b | 2.8 (±2.0)b |
| TNF-alpha (pg/ml) | 3.3 (±1.6) | 3.3 (±1.5) | 3.3 (±1.3) | 3.7 (±1.9)b |
| PAI-1 | 21.9 (±1.1) | 27.6 (±1.2)b | 33 (±1.2)b | 36.5 (±1.5)b |

a Means (±SEM), unless otherwise specified.
b Significantly different from leptin quartile 1, P<0.05 (Dunnett’s test for continuous variables and chi-square test for categorical variables).
c Values from baseline of the Health ABC study

d Values from year 2 of the Health ABC study

doi:10.1371/journal.pone.0140763.t002
among patients with heart failure may be explained by direct antihypertrophic and antiathero-
genic effects of leptin in heart [45, 46].

Although serum leptin has been linked to proinflammatory cytokines, the association of lep-
tin with all-cause mortality and CVD-related mortality was significant after controlling for
inflammatory factors, suggesting that the protective effect of leptin may be independent of the
proinflammatory state. This may be due to the presence of functional leptin receptors on endo-
thelial cells [46, 49]. Through its receptors, leptin causes antihypertrophic effect [46], coronary
vasodilation, activates endothelial progenitor cells and prevents lipid accumulation [44, 45, 49].

The strength of this study includes the longitudinal design of Health ABC study with 10
years of follow-up. HABC’s extensive information on demographic, clinical and biochemical
variables made it possible to control several potential confounders such as physical activity and

| Table 3. Hazard ratios (HR) for all-cause mortality and CVD-related mortality by serum leptin quartile. |
|---------------------------------------------------------------|
| Serum leptin quartiles |
| 1 | 2 | 3 | 4 | P for trendb |
| **All-cause mortality** |
| Men (n) | 354 | 355 | 355 | 355 | 0.241 |
| All-Cause mortality cases (n) | 151 | 139 | 125 | 141 | 0.44 |
| All-Cause mortality (%) | 43 | 39 | 35 | 40 | 0.06 |
| **Model 1b** |
| HR (95% CI) | 1 | 0.97 (0.76–1.23) | 0.79 (0.61–1.01) | 0.88 (0.69–1.12) | 0.63–1.13 | 0.50 |
| **Model 2c** |
| HR (95% CI) | 1 | 0.93 (0.70–1.23) | 0.74 (0.53–1.03) | 0.82 (0.56–1.94) | 0.68 (0.47–0.99) | 0.76 (0.50–1.67) | 0.89 |
| **CVD-related mortality** |
| Men (n) | 354 | 355 | 355 | 355 | 0.48 |
| CVD-related mortality cases (n) | 45 | 53 | 44 | 55 | 0.043 |
| CVD-related mortality % | 12.7 | 14.9 | 12.4 | 15.5 | 0.14 |
| **Model 1b** |
| HR (95% CI) | 1 | 1.96 (0.79–1.83) | 0.99 (0.64–1.53) | 1.09 (0.71–1.67) | 0.71 |
| **Model 2c** |
| HR (95% CI) | 1 | 0.99 (0.61–1.60) | 0.71 (0.40–1.23) | 0.67 (0.35–1.27) | 0.60 (0.37–0.97) | 0.71 |
| **Women (n) | 375 | 375 | 375 | 375 | 0.543 |
| CVD mortality cases (n) | 44 | 36 | 35 | 39 | 0.059 |
| CVD-related mortality % | 11.7 | 9.6 | 9.3 | 10.4 | 0.059 |
| **Model 1b** |
| HR (95% CI) | 1 | 0.60 (0.37–0.97) | 0.71 (0.45–1.25) | 0.76 (0.48–1.21) | 0.48 |
| **Model 2c** |
| HR (95% CI) | 1 | 0.48 (0.27–0.86) | 0.50 (0.27–0.92) | 0.59 (0.29–1.19) | 0.60 (0.37–0.97) | 0.71 |

a Tests for linear trend used leptin as a continuous variable in logistic regression.
b Model 1: Adjusted for age, race, site, years of education, alcohol use, smoking, and physical activity (total calorie intake, HRT use among women and numbers of hours fasted were not significant and did not affect the association between predictor and outcome, so they were not included in the model).
c Model 2: Adjusted for variables in model 1 plus TOTPF, CRP, PAI-1, TNF, and IL6.

doi:10.1371/journal.pone.0140763.t003
inflammatory markers. There are several limitations of this study. Although there may be some differences in leptin levels by race, the sample size did not allow for stratification beyond gender. However, all the analyses were adjusted for race. The Health ABC study only includes white and black participants, so it was not possible to explore these associations among other racial groups. Also, the participants of this study were well-functioning older adults at the baseline, so the findings may not be generalized to older adults with disability or other age groups.

In conclusion, the results of this analysis suggest that moderately elevated leptin levels may be protective for CVD-related mortality in older women. Among men, serum leptin is not associated with reduced risk of all-cause and CVD-related mortality after controlling for body fat and cytokines. The current finding of an inverse association of serum leptin with CVD-related mortality, independent of body fat and inflammatory markers, among older women should be explored in other research studies.

**Author Contributions**

Conceived and designed the experiments: SM NRS. Performed the experiments: SM. Analyzed the data: SM. Contributed reagents/materials/analysis tools: SM NRS. Wrote the paper: SM NRS TBH WH TH MM TSL RL and CV. Critically reviewed the article and contributed important intellectual content: TBH NRS WH TH MM TSL RL CV.

**References**

1. Shimokawa I, Higami Y. Leptin signaling and ageing: insight from caloric restriction. Mech Ageing Dev. 2001; 122:1511–1519. PMID:11511393

2. Yeh S, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr. 1999; 70:183–197. PMID:10426694

3. Hukshom CJ, Lindeman JHN, Toet KH, Saris WHM, Eilers PHC, Plantenga MSW et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab. 2004; 89 (4):1773–1778. PMID:15070944

4. Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54:1994–2002. PMID:15983199

5. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab. 1996; 81:4406–4413. PMID:8954050

6. Moller N, O’Brien P, Nair KS, Disruption of the relationship between fat content and leptin levels with aging in humans. J Clin Metab. 1998; 83:931–934.

7. Bruunsgard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokine. Curr Opin Hematol. 2001; 8:131–136. PMID:11303144

8. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O, Sattar N, et al. The obesity paradox in men with coronary artery disease and heart failure: The role of muscle mass and leptin. Int J Gerontol. 2014; 171 (1): 49–55.

9. Murphy RA, Register TC, Shively CA, Carr JJ, Ge Y, Heilbrun ME, et al. Adipose tissue density, a novel biomarker predicting mortality risk in older adults. J Gerontol A Biol Sci Med Sci. 2014; 69(1):109–117.

10. Claudia L, Bergstrom J, Scheidt C, Pfleischlif J, Barrett E. Cardiovascular death and the metabolic syndrome. Role of adiposity-signaling hormones and inflammatory markers. Diabetes Care. 2006; 29:1363–1369. PMID:16732022

11. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106:3157–3160.

12. Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002; 13:51–59. PMID:11790963

13. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M: Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276:25096–25100. PMID:11342529
14. Beltowski J, Wo´jcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci. 2004; 74:2987–3000. PMID: 15051422

15. Mishra S, Harris TB, Miljkovic I, Satterfield S, De Rekeneire N, et al. Hyperleptinemia, Adiposity, and risk of metabolic syndrome in older adults, Journal of Nutrition and Metabolism. 2013; 327079. doi: 10.1155/2013/327079 PMID: 24455217

16. Gualillo O, Eiras S, Lago F, Dieguez C, Casanueva FF. Evaluated serum leptin concentrations induced by experimental acute inflammation. Life Sci. 2000; 67:2433–2441. PMID: 11065166

17. Bouloumie A, Marumo T, Lafontan M, and Busse R. Leptin Induces Oxidative Stress in Human Endothelial Cells. The FASEB Journal. 1999; 13(10): 1231–1238 PMID: 10385613

18. Van Dielen FM, van’t Veer C, Schols AM, Soetens PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001; 25:1759–1766. PMID: 11781755

19. Perfotto F, Manuso F, Tarquini R 2002 Leukocytosis and hyperleptinemia in obesity: is there a link. Haematologica 87:ELT25. PMID: 12010685

20. Gorina Y, Hoyert D, Lentzner H, Goulding M. Trends in causes of death among older persons States. Aging Trends, No 6. Hyattsville, Maryland: National Center for Health Statistics. 2006.

21. Ren J. Leptin and hyperleptinemia: from friend to foe for cardiovascular function. J Endocrinol. 2004; 181:1–10. PMID: 15072562

22. Francisco L, Godsland IF, Mohammed G, Proudlir AJ, Aldis S, Walton C, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol. 1998; 18: 928–933 PMID: 9633933

23. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104: 3052–6. PMID: 11748999

24. Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooq S, et al. Leptin Predicts a Worsening of the Features of the Metabolic Syndrome Independently of Obesity. Obesity Research. 2005; 13 (8):1476–1484. PMID: 16129731

25. Mendoza-Nunez VM, Garcia AS, Rodriguez MS, Duarte REG, and Yerena R. Overweight, waist circumference, age, gender, and insulin resistance as risk factors for hyperleptinemia. Obes Res. 2002; 10:253–268. PMID: 11943833

26. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, Gualillo O. Mini review: Leptin, from fat to inflammation: old questions and new insights. FEBS Letters; 2005: 579 (2) 295–301. PMID: 15642335

27. Piemonti L, Calori G, Mercalli A, Lattada G, Monti P, Garancini MP, et al. Fasting Plasma Leptin, Tumor Necrosis Factor-α Receptor 2, and Monocyte Chemoattracting Protein 1 Concentration in a Population of Glucose-Tolerant and Glucose-Intolerant Women. Diabetes Care. 2005; 26:2883–2889. PMID: 14514596

28. Brunsgaard H, Pedersen AN, Schroll M, Skinh JP, Pedersen BK. TNF-α, leptin, and lymphocyte function in human aging. Life Sci. 2000; 67: 2721–2731. PMID: 11105988

29. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes. 2002; 51:168–173 PMID: 11756337

30. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Leptinemia is not a risk factor for ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Diabetes Care. 1998; 21:782–786 PMID: 9589240

31. Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB, Mantzoros CS, et al. Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study. Diabetologia 2007; 50:1178–85. PMID: 17372717

32. Operations manual. Health, Aging and Body Composition Study website. Available: https://psg-mac43.ucsf.edu (accessed October, 2009).

33. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978; 31(12):741–55 PMID: 748370

34. Lee JS, Kritchevsky SB, Tylavsky FA, Harris T, Everhart J, Simonsick EM, et al. Weight-loss intention by experimental acute inflammation. Life Sci. 2000; 67:2433–2441. doi: 10.1016/j.atherosclerosis.2010.10.047 PMID: 21176905
36. Lieb W, Sullivan LM, Harris TB, Ronenn Roubenoff R, Levy D, Fox CS, et al. Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals. Diabetes Care. 2009; 32: 612–616. doi:10.2337/dc08-1596 PMID: 19114611

37. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes and Control. 2008; 20: 625–633. doi: 10.1007/s10552-008-9273-z PMID: 19051043

38. Welsh P, Murray HM, Buckley BM, Craen AJMD, Ford I, Jukema JW, et al. Leptin predicts diabetes but not cardiovascular disease: Results from a large prospective study in an elderly population. Diabetes Care. 2009; 32 (2): 308–310. doi:10.2337/dc08-1458 PMID: 19001191

39. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr. 2001; 74:295–301. PMID: 11522551

40. Rosenbaum M, Pietrobelli A, Vasselli JR, Heymsfield SB, Leibel RL. Sexual dimorphism in circulating leptin concentrations is not accounted for by differences in adipose tissue distribution. Int J Obes Relat Metab Disord 2001; 25:1365–71. PMID: 11571601

41. Ruhl CE, Harris TB, Ding J, Goodpaster BH, Kanaya AM, Kritchevsky SB, et al. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. American Journal of Clinical Nutrition. 2007; 85(4):1121–1126. PMID: 17413114

42. Bawngartner RN, Ross RR, Waters DL, Brooks WM, Morley JE, Montoya GD, et al. Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes. Obesity Research. 1999; 7(2):141–149. PMID: 10102250

43. Patel JV, Lim HS, Hughes EA, Lip GY. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk? J Hum hypertens; 2007; 21: 1–4. PMID: 16871286

44. McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, et al. Leptin signaling reduces the severity of cardiac dysfunction and remodeling after chronic ischemic injury. Cardiovasc Res. 2008; 77: 54–63. PMID: 18006469

45. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d’Amati G, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49:293–7. PMID: 10868946

46. Barouch LA, Berkowitz DE, Harrison RW, O’Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003; 108: 754–759. PMID: 12885755

47. Myers MG, Cowley MA, Mu’znberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537–56. PMID: 17937601

48. Unger RH, Zhou YT, and Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl Acad. Sci. 1999; 96: 2327–2332. PMID: 10051641

49. Wolk R, Deb A, Caplice NM. Somers VK. Leptin receptor and functional effects of leptin in human endothelial progenitor cells. Atherosclerosis 2005; 183:131–9. PMID: 15950978